Tenax Therapeutics
NC-based Tenax Therapeutics develops specialty pharmaceuticals for critical care, focusing on Pulmonary Hypertension treatments.
Founded
2008NC-based Tenax Therapeutics develops specialty pharmaceuticals for critical care, focusing on Pulmonary Hypertension treatments.
Founded in Morrisville, North Carolina, Tenax Therapeutics is a specialty pharmaceutical company dedicated to developing and commercializing treatments for critical care markets. Their core mission is to transform the lives of patients through patient-centric and precision medicine approaches. The company focuses on innovative therapies for Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF), utilizing the drug levosimendan. Tenax Therapeutics aims to address significant unmet medical needs with groundbreaking therapies.
Notable figures affiliated with Tenax Therapeutics include experienced professionals in pharmaceutical development and critical care. The company has attracted investment from various stakeholders committed to advancing critical care treatments. Key achievements include the development of efficient clinical trial designs and a passionate focus on orphan diseases with no current disease-modifying treatments. Overall, Tenax Therapeutics has made a significant impact by targeting life-threatening conditions with innovative solutions, striving to improve patient outcomes in the critical care sector.
Companies similar to Tenax Therapeutics include Exodos Life Sciences, Lung Biotechnology, United Therapeutics and Pulmatrix.
Tenax Therapeutics was founded in 2008.
Tenax Therapeutics' headquarters is located in Morrisville, NC, US.
Tenax Therapeutics' most recent funding round was for $15.6M (USD) in February 2023.
As of Feb 3, 2023, Tenax Therapeutics has raised a total of $99.3M (USD).
Tenax Therapeutics has 8 employees as of Feb 6, 2024.
United Therapeutics
